Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

RHY, RHYTHM BIOSCIENCES LIMITED
macdtrader
post Posted: Jul 18 2019, 10:41 AM
  Quote Post


Posts: 37
Thanks: 5


In Reply To: macdtrader's post @ Jul 16 2019, 01:37 PM

Expect a IBX type move here in the next few months.

 
macdtrader
post Posted: Jul 18 2019, 10:41 AM
  Quote Post


Posts: 37
Thanks: 5


In Reply To: macdtrader's post @ Jul 16 2019, 01:37 PM

Expect a IBX type move here in the next few months.

 
macdtrader
post Posted: Jul 16 2019, 01:37 PM
  Quote Post


Posts: 37
Thanks: 5


In Reply To: macdtrader's post @ Jul 16 2019, 01:23 PM

http://sprout8.com/rhy-research-report/

Its a comprehensive report and my cynicism could be unwarranted.

NPV of $1.22 written May 2018.

And I thought I was optimistic.


If they succeed and deliver on the business plan and the test ends up on PBS, then $1.22 looks mega conservative.


Said 'Thanks' for this post: nipper  triage  
 
macdtrader
post Posted: Jul 16 2019, 01:23 PM
  Quote Post


Posts: 37
Thanks: 5


In Reply To: nipper's post @ Nov 26 2018, 03:08 PM

I'm a long term holder here from under 20c.
It's a great story but I'm not buying the long term prospects.
Sprout8 have written some juicy puff pieces on RHY.
The top 50 here, who incidentally control most of the stock are keeping very quiet and are supreme big pocket rampers.
A big bump is coming soon. I just need to decide when to get off. I'd say anywhere between 30c and $1.00 as the short term targe 'and that's a big range.
Its the year of the biotech pump.



Said 'Thanks' for this post: nipper  
 
nipper
post Posted: Nov 26 2018, 03:08 PM
  Quote Post


Posts: 5,879
Thanks: 2129


In Reply To: nipper's post @ Nov 26 2018, 02:34 PM

QUOTE
Australian company Rhythm Biosciences might be a minnow in the market but it has ambitious plans to target more than 100 million people with its colorectal cancer blood test. Trevor Lockett, chief executive of Rhythm Biosciences, said the current test for colorectal cancer was meant to be mass scale, but many people did not want to do a faecal test.

“We knew that the stool test was effective because there was a strong history of reduced mortality among screeners,” Mr Lockett said. “But the uptake rates of stool-based tests are lower than you would like. Most in part by people not wanting to handle their own stool.”

Rhythm’s lead product, ColoSTAT, is intended to be a simple, affordable, minimally invasive and effective blood test. Mr Lockett, a scientist with a background in cancer, said the potential patient population was significant. The incidence of bowel cancer increases dramatically in people above the age of 50 and many countries have screening programs for that age group.

“There are 130 million people in that age group (in our target markets) who are not participating in screening programs and we see those people as essentially a target,” Mr Lockett said. “There is room in that market for more than one test.”

Mr Lockett said the blood test had to be spun out of the CSIRO, where he worked and where ColoSTAT was developed, to become a commercialised product.

“It became apparent that if this was ever going to have an impact on the health of people, it had to end up being a product of some sort,” he said. "We could do whatever research we wanted on grant funding but it would not help us in saving lives.”

The scientist added that it also became clear to him that he had to follow the research out of the CSIRO. “I had spent a long time as ‘theme leader’ for colorectal cancer and gut health in the CSIRO, saying that it was all about impact and getting things out into the market,” he said. “I felt I needed to walk the talk and give this technology its greatest chance of saving lives and helping some investors along the way.”

Mr Lockett said bowel cancer was the “ugly duckling” of cancers at the time he decided to start looking at a new test for the disease. “Colorectal cancer was the great ‘unwashed’. People didn’t talk about it much because it has a gastrointestinal component,” he said.

“It was clear that it was an area that was right for intervention, in the context of diet and lifestyle and also early detection. "It is one of the best examples of something where early detection can lead to far better outcomes. If the cancer is detected early there is 90 per cent survival, whereas later survival can be as low as 10 per cent.”

The company is initially targeting markets in Australia, Europe and the US. Mr Lockett said the funds raised on listing at the end of 2017 were designed to cover the first two years of the company, which meant additional funding would be sourced ahead of that timeline.

He added that the focus was to get the product into the market to save lives and get good returns for investors. [He] said one way of doing that would be a major diagnostic laboratory buying the product but he said any suitor would probably want to see results of clinical trials and some clinical performance.

“There are other incarnations we will need to go through along the way,” he said.
- 100 million??

https://www.theaustralian.com.au/business/u...837493ae9844ab1



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Nov 26 2018, 02:34 PM
  Quote Post


Posts: 5,879
Thanks: 2129


Another one I hadn't heard of . Market Cap $14million

QUOTE
Rhythm Biosciences Limited (RHY) is an early stage company seeking to develop and commercialise Australian medical diagnostics technology for sale to national and international markets. For Rhythm Biosciences, ColoSTAT is the first proposed product-in-development, intended as a test for the accurate and early detection of colorectal cancer.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne

Said 'Thanks' for this post: triage  
 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING